Health
Synairgen’s SNG001 advances into phase 3 COVID-19 trial – PMLiVE
UK biotech had initially been testing drug for COPD and asthma
Southampton, UK-based biotech company Synairgen has announced that a small phase 2 trial of its investigational candidate SNG001 supports advancement into phase 3 testing.
SNG001 delivers an inhaled formulation of Interferon-beta-1a (INF-beta-1a) to the lungs directly via nebulisation – INF-beta is a naturally occurring protein that controls the body’s antiviral response.
Initially, Synairgen had been evaluating the drug as a treatment for COPD and asthma, although its focus has now shifted to investigating…
-
Noosa News19 hours agoMotorbike rider dies after car collision at Kidaman Creek, west of Sunshine Coast
-
General20 hours agoDemocratic senators want an investigation into potential market manipulation from Trump’s inner circle
-
Noosa News23 hours agoBrisbane Man crushed and seriously injured by metal beam in workplace accident at Logan
-
Noosa News21 hours agoVHM’s Goschen Rare Earths and Mineral Sands Project granted 20-year licence